Eagle Victory Clears Way For US Vasopressin Launch
Endo’s Par Fails To Demonstrate Vasostrict Infringement; But CRL Must Be Overcome
Eagle Pharmaceuticals has celebrated a US court ruling that clears the way for it to launch its generic vasopressin rival to Endo’s Vasostrict. However, the company is still waiting for FDA approval after its application was delayed by a CRL earlier this year, with a new action date provided by the agency.
You may also be interested in...
Eagle Pharmaceuticals was gearing up for patent-litigation proceedings with Endo over Vasostrict on 1 February but has quickly seen the landscape shift.
Endo is leaving the door wide open to settle its patent-litigation showdown with Eagle Pharmaceuticals over Vasostrict (vasopressin), after Eagle said it was mulling an ‘at-risk’ launch.
After 180 Life Sciences recently struck a deal with Korea’s Celltrion to support its work in repurposing off-patent biologics, CEO Jim Woody speaks to Generics Bulletin about what the collaboration means for the company and its next steps.